Tower Research Capital (TRC)’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $671K | Buy |
7,715
+4,753
| +160% | +$462K | 0.02% | 729 |
|
|
2025
Q4 | $317K | Buy |
2,962
+1,209
| +69% | +$128K | 0.01% | 1118 |
|
|
2025
Q3 | $177K | Sell |
1,753
-4,358
| -71% | -$405K | ﹤0.01% | 1568 |
|
|
2025
Q2 | $386K | Buy |
6,111
+5,053
| +478% | +$309K | 0.01% | 1197 |
|
|
2025
Q1 | $56K | Sell |
1,058
-3,481
| -77% | -$193K | ﹤0.01% | 2152 |
|
|
2024
Q4 | $254K | Buy |
4,539
+4,161
| +1,101% | +$230K | 0.01% | 1553 |
|
|
2024
Q3 | $19.8K | Sell |
378
-9,547
| -96% | -$457K | ﹤0.01% | 3243 |
|
|
2024
Q2 | $408K | Buy |
9,925
+9,386
| +1,741% | +$375K | 0.01% | 1504 |
|
|
2024
Q1 | $23.4K | Sell |
539
-9,169
| -94% | -$401K | ﹤0.01% | 2863 |
|
|
2023
Q4 | $446K | Buy |
9,708
+8,764
| +928% | +$276K | 0.01% | 1451 |
|
|
2023
Q3 | $21.6K | Sell |
944
-2,806
| -75% | -$62.8K | ﹤0.01% | 3298 |
|
|
2023
Q2 | $61.8K | Sell |
3,750
-13,463
| -78% | -$243K | ﹤0.01% | 2412 |
|
|
2023
Q1 | $307K | Buy |
17,213
+3,463
| +25% | +$87K | 0.01% | 1126 |
|
|
2022
Q4 | $400K | Buy |
13,750
+5,276
| +62% | +$136K | 0.02% | 831 |
|
|
2022
Q3 | $207K | Buy |
8,474
+2,670
| +46% | +$49.7K | ﹤0.01% | 1905 |
|
|
2022
Q2 | $25K | Sell |
5,804
-28,704
| -83% | -$157K | ﹤0.01% | 3573 |
|
|
2022
Q1 | $397K | Buy |
34,508
+31,990
| +1,270% | +$281K | ﹤0.01% | 1288 |
|
|
2021
Q4 | $25K | Sell |
2,518
-679
| -21% | -$7.63K | ﹤0.01% | 3435 |
|
|
2021
Q3 | $41K | Sell |
3,197
-538
| -14% | -$8.22K | ﹤0.01% | 3118 |
|
|
2021
Q2 | $73K | Buy |
3,735
+1,461
| +64% | +$30.3K | ﹤0.01% | 2692 |
|
|
2021
Q1 | $48K | Buy |
2,274
+1,490
| +190% | +$43.2K | ﹤0.01% | 3161 |
|
|
2020
Q4 | $23K | Sell |
784
-1,233
| -61% | -$31.3K | ﹤0.01% | 3781 |
|
|
2020
Q3 | $44K | Sell |
2,017
-767
| -28% | -$17.6K | ﹤0.01% | 3586 |
|
|
2020
Q2 | $62K | Buy |
+2,784
| New | +$54.3K | ﹤0.01% | 2881 |
|
|
2019
Q4 | – | Sell |
-603
| Closed | -$13K | – | 4258 |
|
|
2019
Q3 | $13K | Buy |
+603
| New | +$12.9K | ﹤0.01% | 2783 |
|
|
2019
Q2 | – | Sell |
-1,095
| Closed | -$30K | – | 4199 |
|
|
2019
Q1 | $30K | Buy |
1,095
+859
| +364% | +$24.7K | ﹤0.01% | 2045 |
|
|
2018
Q4 | $7K | Buy |
236
+187
| +382% | +$5.17K | ﹤0.01% | 2707 |
|
|
2018
Q3 | $1K | Sell |
49
-375
| -88% | -$11.8K | ﹤0.01% | 3614 |
|
|
2018
Q2 | $13K | Buy |
424
+32
| +8% | +$875 | ﹤0.01% | 2671 |
|
|
2018
Q1 | $8K | Buy |
+392
| New | +$10.4K | ﹤0.01% | 2562 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
Tower Research Capital (TRC)'s RYTM Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Rhythm Pharmaceuticals (RYTM) stake by 160% in Q1 2026, buying an estimated $462K and bringing the position to 7,715 shares worth $671K. The position accounts for 0.02% of the portfolio, ranked #729.
Tower Research Capital (TRC) first reported a position in RYTM in Q1 2018 and has held it in 30 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- Tower Research Capital (TRC) held 7,715 shares of Rhythm Pharmaceuticals worth $671K as of Q1 2026.
- Tower Research Capital (TRC) bought 4,753 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $462K.
- Rhythm Pharmaceuticals made up 0.02% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #729 holding.
- Tower Research Capital (TRC) first reported a position in Rhythm Pharmaceuticals in Q1 2018 and has held it in 30 quarters since.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.